source
- House panel urges FDA to bar Chinese clinical trial data from drug applicationsA House spending committee introduced language urging the FDA to prohibit the use of clinical trial data generated in China when reviewing new drug applications. The proposal reflects concerns abo…
- FDA oncology panel votes against AstraZeneca's camizestrant trial, citing lack of meaningful benefitThe FDA's oncology advisory committee convened for the first time in about nine months and evaluated AstraZeneca's late-stage trial of its oral selective estrogen receptor degrader, camizestrant.…